On February 28, Bide Pharmatech (688073.SH) released its 2025 preliminary earnings estimate, delivering an outstanding report card with strong growth in both revenue and net profit. The report shows that the company achieved a total annual operating revenue of 1.3238 billion yuan (RMB 1,323,810,700) in 2025, a year-on-year increase of 20.13%; the net profit attributable to owners of the parent company was 152.2 million yuan, a year-on-year increase of 29.61%; and the net profit after deducting non-recurring gains and losses was 133.12 million yuan, a year-on-year increase of 27.98%. This series of excellent data not only highlights the company’s robust operational strength but also marks a solid step forward on its path of high-quality development.
As an enterprise deeply engaged in the front end of the innovative drug R&D industry chain since its establishment in 2007, Bide Pharmatech has grown into a national-level specialized and sophisticated “Little Giant” enterprise. Its core business is providing professional and efficient drug molecular building blocks, as well as scientific reagent products and services, for global innovative drug R&D institutions. Relying on its core competitive advantages of “variety, speed, quality, and cost-effectiveness” and the model of “horizontally expanding product varieties while vertically deepening advantageous product lines,” the company has accumulated 140,000 types of standing spot inventory. It can provide customers with nearly one million products featuring novel structures and diverse functions, covering the entire process from drug target discovery to compound synthesis. Its end customers include multinational pharmaceutical giants such as Roche, Merck, and Pfizer; domestic innovative pharmaceutical companies such as Hengrui Medicine and BeiGene; well-known CRO institutions such as Pharmaron and Medicilon; and numerous top domestic and international research institutes.
An in-depth analysis of the driving force behind this performance growth reveals that Bide Pharmatech’s globalization strategy and refined management have yielded remarkable results. During the reporting period, the company adhered to its global development strategy. While deeply cultivating the domestic market, it continued to strengthen the marketing and promotion of its overseas business, driving steady growth in overseas operations. In addition, the company actively increased its product innovation efforts, continuously optimized its product structure, and created value through R&D. Simultaneously, it consistently advanced intelligent operations and comprehensively improved management efficiency, ensuring that not only did operating revenue achieve steady growth, but profitability indicators such as gross profit margin and profit margin also continued to improve.
During the “15th Five-Year Plan” period, the state will strongly support the innovative development of the biomanufacturing industry, promoting the pharmaceutical industry’s transformation from “follower-style innovation” to “systematic innovation,” from “scale-and-speed-oriented growth” to “quality-and-efficiency-oriented growth,” and from a “traditional business model” to “supply chain digitalization”. Bide Pharmatech’s practice of continuously optimizing its product structure and improving management efficiency to achieve a higher profit margin in 2025 is a vivid interpretation of “quality-and-efficiency-oriented growth”. Relying on its rich product pipeline, global footprint, and highly cost-effective solutions, Bide Pharmatech is poised to continuously empower global innovative drug R&D and embrace broader development space with the tailwinds of favorable policies.